

**Freedom of Information Act 2000 - Request Reference FoI/23/475**

**Use of Biologic Medicines in Dermatology**

**Information Requested:**

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira: 10
- Adalimumab Biosimilar: 149
- Apremilast: \*
- Bimekizumab: 8
- Brodalumab: 5
- Certolizumab: 5
- Deucravacitinib: 0
- Dimethyl fumarate: 0
- Etanercept - Enbrel: 0
- Etanercept Biosimilar: 5
- Guselkumab: 17
- Infliximab - Remicade: 0
- Infliximab Biosimilar: 14
- Ixekizumab: 11
- Risankizumab: 42
- Secukinumab: 30
- Tildrakizumab: \*
- Ustekinumab: 39

Please note that Section 40(2) of the Freedom of Information Act 2000 has been applied where information above has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (less than 5). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.